{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:28:37Z","timestamp":1761802117139,"version":"build-2065373602"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Symdeko, a cystic fibrosis transmembrane conductance regulator (CFTR), is widely utilized for treating cystic fibrosis (CF). Although its safety has been validated in numerous clinical trials, the real-world safety profile still needs further investagation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed adverse event (AE) reports related to Symdeko from the FDA Adverse Event Reporting System (FAERS) spanning Q1 2018 to Q3 2024. Four disproportionality analysis methods were employed: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multi-Item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN). A descriptive analysis of the time to onset (TTO) of AEs was conducted, and the Weibull distribution was used to predict temporal variations in AEs. Sensitivity analysis was also implemented to refine the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 5,245 AE reports. Of these, 54.9% were from females, 41.3% from males, and 62.3% from healthcare professionals. The study confirmed several known AEs, including headache, nausea, and elevated liver enzymes, and identified novel signals, such as anxiety, depression, suicidal ideation, and renal stones. In females, particular attention should be paid to dizziness, anxiety, and lower respiratory infections. In males, the occurrence of nausea and abdominal pain should be noted. For patients aged 18 and older, kidney stones should be monitored. The median time to onset (TTO) of AEs was 188 days, with 51.3% of AEs occurring after six months of treatment initiation. Sensitivity analysis further confirmed that headache, nausea, anxiety, depression, suicidal ideation, and renal stones continued to exhibit positive signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study confirmed several known AEs associated with Symdeko and identified various novel signals, providing preliminary real-world safety evidence for Symdeko. These findings underscore the importance of ongoing monitoring and management for patients treated with Symdeko. Future larger-scale prospective studies are necessary to validate these findings and enhance patient management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1681985","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:24:02Z","timestamp":1761801842000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety of Symdeko: insights from the food and drug administration adverse event reporting system"],"prefix":"10.3389","volume":"12","author":[{"given":"Su","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review.","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jcf.2025.02.005","article-title":"Evaluation of clinical practice guidelines on treatment of cystic fibrosis: a systematic review.","volume":"24","author":"Huang","year":"2025","journal-title":"J Cyst Fibros."},{"key":"B3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1164\/rccm.201606-1107CI","article-title":"Early lung disease in infants and preschool children with cystic fibrosis. what have we learned and what should we do about It?","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/s0140-6736(20)32542-3","article-title":"Cystic fibrosis.","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"190068","DOI":"10.1183\/16000617.0068-2019","article-title":"Cftr targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.","volume":"29","author":"Patel","year":"2020","journal-title":"Eur Respir Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"116120","DOI":"10.1016\/j.ejmech.2023.116120","article-title":"Small molecule modulators of cystic fibrosis transmembrane conductance regulator (Cftr): structure, classification, and mechanisms.","volume":"265","author":"Cao","year":"2024","journal-title":"Eur J Med Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.NPR.0000547548.63764.6b","article-title":"Drug updates and approvals: 2018 in review.","volume":"43","author":"Mospan","year":"2018","journal-title":"Nurse Pract."},{"key":"B9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/17460441.2020.1750592","article-title":"The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.","volume":"15","author":"Guerra","year":"2020","journal-title":"Expert Opin Drug Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of Cf airway epithelial cell function in vitro by a Cftr potentiator, Vx-770.","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of Vx-770 in persons with cystic fibrosis and the G551d-Cftr mutation.","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1164\/rccm.201704-0717OC","article-title":"Tezacaftor\/Ivacaftor in subjects with cystic fibrosis and F508del\/F508del-Cftr or F508del\/G551d-Cftr.","volume":"197","author":"Donaldson","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"Cd010966","DOI":"10.1002\/14651858.CD010966.pub2","article-title":"Correctors (specific therapies for class ii cftr mutations) for cystic fibrosis.","volume":"8","author":"Southern","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1524159","DOI":"10.3389\/fphar.2025.1524159","article-title":"Real-world pharmacovigilance investigation of imipenem\/cilastatin: signal detection using the fda adverse event reporting system (Faers) database.","volume":"16","author":"Jia","year":"2025","journal-title":"Front Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","article-title":"Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of faers data.","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41598-025-86976-y","article-title":"A real-world pharmacovigilance study of brodalumab based on the fda adverse event reporting system.","volume":"15","author":"He","year":"2025","journal-title":"Sci Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the fda adverse event reporting system.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (Prrs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in singapore - a comparison of three different disproportionality measures.","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children.","volume":"95","author":"Rivkees","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcf.2020.07.023","article-title":"A Phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-Cftr mutation and a residual function mutation.","volume":"20","author":"Davies","year":"2021","journal-title":"J Cyst Fibros."},{"key":"B23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jcf.2022.12.006","article-title":"Long-term Tezacaftor\/Ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-Cftr Mutation: 96-week, open-label extension of the extend trial.","volume":"22","author":"Flume","year":"2023","journal-title":"J Cyst Fibros."},{"key":"B24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from Gbd2019.","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain."},{"key":"B25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jcf.2017.07.001","article-title":"Retrospective observational study of french patients with cystic fibrosis and a Gly551asp-Cftr mutation after 1 and 2years of treatment with ivacaftor in a real-world setting.","volume":"17","author":"Hubert","year":"2018","journal-title":"J Cyst Fibros."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2147\/tcrm.S165027","article-title":"Profile of tezacaftor\/ivacaftor combination and its potential in the treatment of cystic fibrosis.","volume":"15","author":"Shiferaw","year":"2019","journal-title":"Ther Clin Risk Manag."},{"key":"B27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of cftr modulators in the treatment of cystic fibrosis: a systematic review.","volume":"10","author":"Dagenais","year":"2020","journal-title":"J Clin Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1002\/ncp.11122","article-title":"Cystic Fibrosis and fat malabsorption: pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective Cftr modulator therapy.","volume":"39","author":"McDonald","year":"2024","journal-title":"Nutr Clin Pract."},{"key":"B29","doi-asserted-by":"publisher","first-page":"17534666221144211","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis.","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther Adv Respir Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1156621","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: a case series.","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor therapy.","volume":"22","author":"Arslan","year":"2023","journal-title":"J Cyst Fibros."},{"key":"B32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/mcp.0000000000001014","article-title":"Neuropsychiatric adverse effects from Cftr modulators deserve a serious research effort.","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr Opin Pulm Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.3390\/jcm13195806","article-title":"Treatment of psychological symptoms in patients with cystic fibrosis.","volume":"13","author":"Campagna","year":"2024","journal-title":"J Clin Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3892\/ijmm.2021.4982","article-title":"Recent advances on the mechanisms of kidney stone formation (review).","volume":"48","author":"Wang","year":"2021","journal-title":"Int J Mol Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1089\/end.2021.0151","article-title":"Systematic review of the prevalence of kidney stones in cystic fibrosis.","volume":"35","author":"Moryousef","year":"2021","journal-title":"J Endourol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.advnut.2023.03.002","article-title":"Kidney stone prevention.","volume":"14","author":"Peerapen","year":"2023","journal-title":"Adv Nutr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"sfae256","DOI":"10.1093\/ckj\/sfae256","article-title":"Kidney effects of triple Cftr modulator therapy in people with cystic fibrosis.","volume":"17","author":"Gabai","year":"2024","journal-title":"Clin Kidney J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis.","volume":"16","author":"Singh","year":"2017","journal-title":"J Cyst Fibros."},{"key":"B39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.prrv.2018.03.007","article-title":"Urinary tract stones in cystic fibrosis.","volume":"27","author":"Young","year":"2018","journal-title":"Paediatr Respir Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/ki.2013.104","article-title":"The role of oxalobacter formigenes colonization in calcium oxalate stone disease.","volume":"83","author":"Siener","year":"2013","journal-title":"Kidney Int."},{"key":"B41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00240-021-01244-8","article-title":"Urinary stone disease prevalence and associations in cystic fibrosis.","volume":"49","author":"Wright","year":"2021","journal-title":"Urolithiasis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1681985\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:24:03Z","timestamp":1761801843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1681985\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":41,"alternative-id":["10.3389\/fmed.2025.1681985"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1681985","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"1681985"}}